샘플 요청 목록

 카트 문의
시장보고서
상품코드
1765373

세계의 암 악액질 시장

Cancer Cachexia
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 255 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

암 악액질 세계 시장은 2030년까지 37억 달러에 달할 전망

2024년에 27억 달러로 추정되는 암 악액질 세계 시장은 분석 기간인 2024-2030년에 CAGR 5.7%로 성장하여 2030년에는 37억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 황체 호르몬은 CAGR 5.9%를 기록하며 분석 기간 종료시에는 15억 달러에 달할 것으로 예상됩니다. 코르티코스테로이드 분야의 성장률은 분석 기간 동안 CAGR 5.1%로 추정됩니다.

미국 시장은 9억 8,550만 달러로 추정, 중국은 CAGR 7.6%로 성장 예측

미국의 암 악액질 시장은 2024년에는 9억 8,550만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 3억 1,400만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 4.4%와 4.8%로 예측됩니다. 유럽에서는 독일이 CAGR 5.4%로 성장할 것으로 예측됩니다.

세계의 암 악액질 시장 - 주요 동향과 촉진요인 정리

암 악액질은 심한 체중 감소, 근력 저하, 식욕부진을 특징으로 하는 다인자 증후군으로 암 환자의 삶의 질과 생존율에 큰 영향을 미치는 질환입니다. 일반적인 영양실조와 달리 암 악액질은 종양과 이에 대한 신체의 반응과 관련된 복잡한 대사 변화와 염증으로 인해 발생합니다. 이 증후군은 단백질과 에너지의 균형이 깨져 기존의 영양 지원으로는 쉽게 회복되지 않습니다. 암 악액질 치료제는 암 환자의 심각한 체중 감소, 근육 위축, 식욕 부진을 특징으로 하는 복잡하고 쇠약해진 암 악액질 증후군을 치료하는 데 초점을 맞추고 있습니다. 이 증상은 환자의 삶의 질, 치료 효과 및 전반적인 예후에 큰 영향을 미칩니다. 일반적인 영양실조와 달리 암 악액질은 전신 염증, 대사 이상, 호르몬 변화 등 복합적인 요인에 의해 발생하며, 단백질과 에너지의 균형이 무너져 단백질과 에너지의 균형이 깨집니다. 기존의 영양 보충만으로는 충분하지 않으며, 표적 치료제의 개발이 필요합니다. 암 악액질 치료제의 현재 접근법에는 항염증제, 식욕 증진제, 단백 동화 스테로이드, 대사 경로를 조절하여 근육량을 유지하고 환자의 예후를 개선하는 약제 등이 있습니다.

암 악액질의 근본적인 메커니즘이 밝혀지면서 몇 가지 유망한 치료 표적이 확인되었습니다. 예를 들어, TNF-α나 IL-6와 같은 염증성 사이토카인을 표적으로 하는 약물은 전신 염증을 억제할 수 있는 것으로 연구되고 있습니다. 또한, 그렐린 작용제 및 기타 식욕 증진제는 식욕부진에 대항하고 칼로리 섭취를 개선하는 것을 목표로 하고 있습니다. 선택적 안드로겐 수용체 조절제(SARM)와 같은 단백 동화 작용을 하는 약물은 근육 단백질 합성을 촉진하고 근육 소모를 방지하기 위해 연구되고 있습니다. 또한, 악액질의 여러 측면을 동시에 치료하는 병용요법이 개발되고 있어 보다 종합적인 치료 접근법을 제공하고 있습니다. 이러한 발전은 다인성 증후군에 효과적으로 대처하기 위한 다각적인 전략이 필요하다는 인식이 확산되고 있음을 반영합니다.

암 악액질 치료제 시장의 성장은 암 유병률 증가, 암에 대한 인식 증가, 치료 연구 진행 등 여러 요인에 의해 주도되고 있습니다. 전 세계적으로 암 환자의 증가는 당연히 악액질 발생률의 증가로 이어져 효과적인 치료에 대한 시급한 필요성이 부각되고 있습니다. 의료진과 환자들 사이에서 악액질이 암 치료 결과에 미치는 영향이 크다는 인식이 높아지면서 전문 치료제에 대한 수요가 증가하고 있습니다. 지속적인 연구개발 노력으로 새로운 치료제 후보물질이 개발되고 기존 치료제가 최적화되면서 시장 성장을 더욱 촉진하고 있습니다. 또한, 암 연구에 대한 정부의 지원 정책과 자금 지원은 새로운 치료법의 개발 및 승인을 촉진하고 있습니다. 환자 개개인의 유전적, 대사적 프로파일에 따라 치료하는 맞춤형 의료로의 전환은 보다 표적화되고 효과적인 악액질 치료의 채택을 촉진할 것으로 예상됩니다. 전반적으로, 악액질 치료제 시장은 새로운 치료법의 출현과 기존 치료법의 개선으로 이 어려운 질환에 더 잘 대처할 수 있게 됨에 따라 크게 확대될 것으로 예상됩니다.

부문

치료제(황체 호르몬, 부신피질 호르몬, 병용요법, 기타 치료제), 최종사용자(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Charles River Laboratories International, Inc.
  • Aphios Corporation
  • Fresenius SE & Co. KGaA
  • AbbVie, Inc.
  • AVEO Pharmaceuticals, Inc.
  • AAVogen, Inc.
  • Immuneering
  • Caelus Health
  • AliveGen USA
  • Endevica Bio
  • Extend Biosciences

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범에 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • NSAID
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm 25.07.15

Global Cancer Cachexia Market to Reach US$3.7 Billion by 2030

The global market for Cancer Cachexia estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Progestogens, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$985.5 Million While China is Forecast to Grow at 7.6% CAGR

The Cancer Cachexia market in the U.S. is estimated at US$985.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$314.0 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Cancer Cachexia Market - Key Trends & Drivers Summarized

Cancer cachexia is a multifactorial syndrome characterized by severe body weight loss, muscle wasting, and anorexia, significantly impacting the quality of life and survival rates of cancer patients. Unlike general malnutrition, cancer cachexia is driven by complex metabolic changes and inflammation associated with the tumor and the body's response to it. This syndrome leads to a negative protein and energy balance, which is not easily reversed by conventional nutritional support. Cancer cachexia therapeutics are focused on addressing the complex and debilitating syndrome of cancer cachexia, characterized by severe weight loss, muscle atrophy, and anorexia in cancer patients. This condition significantly impacts patient quality of life, treatment efficacy, and overall prognosis. Unlike general malnutrition, cancer cachexia is driven by a combination of factors including systemic inflammation, metabolic dysregulation, and hormonal changes that lead to a negative protein and energy balance. Traditional nutritional support alone is insufficient, necessitating the development of targeted therapeutics. Current approaches in cancer cachexia therapeutics include anti-inflammatory agents, appetite stimulants, anabolic steroids, and agents that modulate metabolic pathways to preserve muscle mass and improve patient outcomes.

Advancements in the understanding of cancer cachexia's underlying mechanisms have led to the identification of several promising therapeutic targets. For instance, drugs targeting pro-inflammatory cytokines such as TNF-alpha and IL-6 are being investigated for their potential to reduce systemic inflammation. Additionally, ghrelin agonists and other appetite stimulants aim to counteract anorexia and improve caloric intake. Anabolic agents such as selective androgen receptor modulators (SARMs) are being explored to promote muscle protein synthesis and prevent muscle wasting. Furthermore, combination therapies that address multiple aspects of cachexia simultaneously are under development, offering a more comprehensive approach to treatment. These advancements reflect a growing recognition of the need for multifaceted strategies to effectively combat this multifactorial syndrome.

The growth in the cancer cachexia therapeutics market is driven by several factors, including the rising prevalence of cancer, increased awareness of the condition, and ongoing advancements in therapeutic research. The global increase in cancer cases naturally leads to a higher incidence of cachexia, highlighting the urgent need for effective treatments. Greater awareness among healthcare providers and patients about the significant impact of cachexia on cancer treatment outcomes has spurred demand for specialized therapeutics. Continuous research and development efforts are yielding new therapeutic candidates and optimizing existing ones, further propelling market growth. Additionally, supportive government policies and funding for cancer research are facilitating the development and approval of novel treatments. The shift towards personalized medicine, with therapies tailored to individual patients' genetic and metabolic profiles, is also expected to drive the adoption of more targeted and effective cachexia treatments. Overall, the cancer cachexia therapeutics market is poised for significant expansion as new therapies emerge and existing ones are refined to better address this challenging condition.

SCOPE OF STUDY:

The report analyzes the Cancer Cachexia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutics (Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics); End-Use (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 50 Featured) -

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Charles River Laboratories International, Inc.
  • Aphios Corporation
  • Fresenius SE & Co. KGaA
  • AbbVie, Inc.
  • AVEO Pharmaceuticals, Inc.
  • AAVogen, Inc.
  • Immuneering
  • Caelus Health
  • AliveGen USA
  • Endevica Bio
  • Extend Biosciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Cancer: An Insight
    • A Prelude to Cancer Cachexia
    • Cachexia Treatment
    • Pharmacologic Approaches for Clinical Management of Cancer Cachexia
    • Cancer Cachexia Market Faces a Challenge Amid the Pandemic
    • Percentage YoY Change in Sales of Select Physician-Administered Oncology Products Chemotherapy Administration: (March-June) 2019 Vs 2020March
    • Pandemic Impact on Cancer Research
    • Tariff Impact on Global Supply Chain Patterns
    • Cancer Cachexia - Global Key Competitors Percentage Market Share in 2025 (E)
    • Global Market Prospects and Outlook
    • Progestogens Account for a Major Share, Combination Therapies to Drive Growth
    • North America and Europe Constitute Major Regions, Asia-Pacific Exhibits the Fastest Growth
    • Competition
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Recent Market Activity
    • Market Challenges
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rise in Number of Cancer Cases, and High Prevalence of Cancer Cachexia to Drive Market Growth
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities
    • Promising Treatment Options Drive Market Gains
  • NSAID
    • Erythropoietin
    • IL-1a, IL-6 & TNFa Inhibitors
    • Myostatin Inhibitors
    • Appetite & Metabolism Modulators
    • Cytokine Modulator
    • Anabolic Agents
    • Combination Therapies
    • DNA Link to throw More Light on Cancer Cachexia
    • Ageing Demographics to Drive Market Demand
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Cancer Research Spending Continues to Witness Growth
    • Pipeline Analysis
    • Macimorelin from AEterna Zentaris
    • PF- 06946860 from Pfizer
    • TCMCB07 from Endevica Bio
    • Actimed Therapeutics S-pindolol
    • Lenalidomide
    • AV-380
    • Select Unimodal Treatment Agents for Cancer Cachexia Currently Under Clinical Trial
    • Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome
    • Select Key Developments
    • Helsinn Launches Adlumiz for Cancer Cachexia Patients in Japan
    • Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
    • Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
    • Researchers Develop New Drug with Potential to Improve & Treat Cancer Cachexia
    • Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
    • Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
    • ESMO Publishes New Guidelines on Cachexia Management in Adult Cancer Patients
    • Uptrend in Healthcare Spending Drives Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer Cachexia Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Progestogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combination Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Facts & Figures
    • US Cancer Cachexia Market Share (in %) by Company: 2022 & 2030
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • JAPAN
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • CHINA
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • EUROPE
    • Market Facts & Figures
    • European Cancer Cachexia Market: Competitor Market Share Scenario (in %) for 2022 & 2030
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • FRANCE
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • GERMANY
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of World 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제